Comparative efficacy of ripertamab, rituximab, and efgartigimod in chronic inflammatory demyelinating polyneuropathy: an exploratory real-world multicenter cohort study.
Wu Y, Zhou Y, Yin W, Zhao X, Xu L, Su Y, Wang S, Li S, Wang Y, Duan C, et al.
Front Immunol. 2026; 17:1825584. PMID: 42238571.Abstract
